Skip to content
lifestyle.womensconference.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Boehringer Ingelheim Limited
Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer
April 28, 2026
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
April 9, 2026
Boehringer Ingelheim’s Athens Site Achieves Carbon Neutral Operations, Advancing 2030 Commitments
April 6, 2026
Boehringer Ingelheim and Connecticut Science Center Launch an Innovation Lab to Advance STEM Education Across Connecticut
March 26, 2026
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
March 25, 2026
Global survey reveals pet owners lack awareness of parasite risks and seek clearer prevention advice
March 18, 2026
Boehringer Ingelheim Granted Emergency Use Authorization for New World Screwworm Treatments in Dogs and Cats
February 19, 2026
Boehringer Ingelheim Secures Emergency Use Authorization for IVOMEC® (ivermectin) 1% Injection to Help Protect Cattle Against New World Screwworm
February 10, 2026
Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial
January 28, 2026
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
January 27, 2026
←
Previous Page
1
2